Institution
Montreal Children's Hospital
Healthcare•Montreal, Quebec, Canada•
About: Montreal Children's Hospital is a healthcare organization based out in Montreal, Quebec, Canada. It is known for research contribution in the topics: Population & Poison control. The organization has 3842 authors who have published 4816 publications receiving 200198 citations.
Topics: Population, Poison control, Gene, Medicine, Kidney
Papers published on a yearly basis
Papers
More filters
University of Toronto1, Stanford University2, German Cancer Research Center3, Ludwig Maximilian University of Munich4, Duke University5, Cincinnati Children's Hospital Medical Center6, Harvard University7, Brigham and Women's Hospital8, Boston Children's Hospital9, Massachusetts Institute of Technology10, University of British Columbia11, Montreal Children's Hospital12, New York University13, Instituto Português de Oncologia Francisco Gentil14, Hospital Sant Joan de Déu Barcelona15, Alfred I. duPont Hospital for Children16, Children's National Medical Center17, Heidelberg University18
TL;DR: Subgroup-specific differences in the location and timing of recurrence across medulloblastoma subgroups have potential treatment ramifications and intensified local (posterior fossa) therapy should be tested in the initial treatment of patients with SHH tumours.
Abstract: Summary Background Recurrent medulloblastoma is a therapeutic challenge because it is almost always fatal. Studies have confirmed that medulloblastoma consists of at least four distinct subgroups. We sought to delineate subgroup-specific differences in medulloblastoma recurrence patterns. Methods We retrospectively identified a discovery cohort of all recurrent medulloblastomas at the Hospital for Sick Children (Toronto, ON, Canada) from 1994 to 2012 (cohort 1), and established molecular subgroups using a nanoString-based assay on formalin-fixed paraffin-embedded tissues or frozen tissue. The anatomical site of recurrence (local tumour bed or leptomeningeal metastasis), time to recurrence, and survival after recurrence were assessed in a subgroup-specific manner. Two independent, non-overlapping cohorts (cohort 2: samples from patients with recurrent medulloblastomas from 13 centres worldwide, obtained between 1991 and 2012; cohort 3: samples from patients with recurrent medulloblastoma obtained at the NN Burdenko Neurosurgical Institute [Moscow, Russia] between 1994 and 2011) were analysed to confirm and validate observations. When possible, molecular subgrouping was done on tissue obtained from both the initial surgery and at recurrence. Results Cohort 1 consisted of 30 patients with recurrent medulloblastomas; nine with local recurrences, and 21 with metastatic recurrences. Cohort 2 consisted of 77 patients and cohort 3 of 96 patients with recurrent medulloblastoma. Subgroup affiliation remained stable at recurrence in all 34 cases with available matched primary and recurrent pairs (five pairs from cohort 1 and 29 pairs from cohort 2 [15 SHH, five group 3, 14 group 4]). This finding was validated in 17 pairs from cohort 3. When analysed in a subgroup-specific manner, local recurrences in cohort 1 were more frequent in SHH tumours (eight of nine [89%]) and metastatic recurrences were more common in group 3 and group 4 tumours (17 of 20 [85%] with one WNT, p=0·0014, local vs metastatic recurrence, SHH vs group 3 vs group 4). The subgroup-specific location of recurrence was confirmed in cohort 2 (p=0·0013 for local vs metastatic recurrence, SHH vs group 3 vs group 4,), and cohort 3 (p Interpretation Medulloblastoma does not change subgroup at the time of recurrence, reinforcing the stability of the four main medulloblastoma subgroups. Significant differences in the location and timing of recurrence across medulloblastoma subgroups have potential treatment ramifications. Specifically, intensified local (posterior fossa) therapy should be tested in the initial treatment of patients with SHH tumours. Refinement of therapy for patients with group 3 or group 4 tumours should focus on metastases. Funding Canadian Institutes of Health Research, National Institutes of Health, Pediatric Brain Tumor Foundation, Garron Family Chair in Childhood Cancer Research at The Hospital for Sick Children and The University of Toronto.
296 citations
The Centre for Applied Genomics1, University of Toronto2, Paris Diderot University3, Pasteur Institute4, Centre national de la recherche scientifique5, McMaster University6, Université de Montréal7, Heidelberg University8, French Institute of Health and Medical Research9, Lund University10, University College London11, University of Gothenburg12, Montreal Children's Hospital13, University of Alberta14, Memorial University of Newfoundland15
TL;DR: A hemizygous SHANK1 deletion is identified that segregates in a four-generation family in which male carriers--but not female carriers--have ASD with higher functioning, and the discovery of apparent reduced penetrance of ASD in females bearing inherited autosomal SHank1 deletions provides a possible contributory model for the male gender bias in autism.
Abstract: Recent studies have highlighted the involvement of rare ( 15,000 controls (p = 0.009). The discovery of apparent reduced penetrance of ASD in females bearing inherited autosomal SHANK1 deletions provides a possible contributory model for the male gender bias in autism. The data are also informative for clinical-genetics interpretations of both inherited and sporadic forms of ASD involving SHANK1.
295 citations
Boston University1, Montreal Children's Hospital2, Canadian Blood Services3, New York University4, Albany Medical College5, University of Chicago6, Dartmouth College7, University of Washington8, Hacettepe University9, University of Tennessee Health Science Center10, University of Pittsburgh11, Northwestern University12, University of Milano-Bicocca13, Universidad del Desarrollo14, University of Sydney15, Southmead Hospital16, University of Florida17, William Mitchell College of Law18, University of Melbourne19, University of Cape Town20, Dubai Hospital21, University of Valencia22, University of Toronto23, The Queen's Medical Center24, University of Texas Health Science Center at Houston25, Seoul National University Bundang Hospital26, Sir Charles Gairdner Hospital27, Texas A&M University28, Kagawa University29, Capital Medical University30, Tribhuvan University31, Indiana University – Purdue University Indianapolis32, Montreal Neurological Institute and Hospital33, Ruby Hall Clinic34, University of Southern California35
TL;DR: Recommendations are provided for the minimum clinical standards for determination of brain death/death by neurologic criteria in adults and children with clear guidance for various clinical circumstances and have widespread international society endorsement.
Abstract: Importance There are inconsistencies in concept, criteria, practice, and documentation of brain death/death by neurologic criteria (BD/DNC) both internationally and within countries. Objective To formulate a consensus statement of recommendations on determination of BD/DNC based on review of the literature and expert opinion of a large multidisciplinary, international panel. Process Relevant international professional societies were recruited to develop recommendations regarding determination of BD/DNC. Literature searches of the Cochrane, Embase, and MEDLINE databases included January 1, 1992, through April 2020 identified pertinent articles for review. Because of the lack of high-quality data from randomized clinical trials or large observational studies, recommendations were formulated based on consensus of contributors and medical societies that represented relevant disciplines, including critical care, neurology, and neurosurgery. Evidence Synthesis Based on review of the literature and consensus from a large multidisciplinary, international panel, minimum clinical criteria needed to determine BD/DNC in various circumstances were developed. Recommendations Prior to evaluating a patient for BD/DNC, the patient should have an established neurologic diagnosis that can lead to the complete and irreversible loss of all brain function, and conditions that may confound the clinical examination and diseases that may mimic BD/DNC should be excluded. Determination of BD/DNC can be done with a clinical examination that demonstrates coma, brainstem areflexia, and apnea. This is seen when (1) there is no evidence of arousal or awareness to maximal external stimulation, including noxious visual, auditory, and tactile stimulation; (2) pupils are fixed in a midsize or dilated position and are nonreactive to light; (3) corneal, oculocephalic, and oculovestibular reflexes are absent; (4) there is no facial movement to noxious stimulation; (5) the gag reflex is absent to bilateral posterior pharyngeal stimulation; (6) the cough reflex is absent to deep tracheal suctioning; (7) there is no brain-mediated motor response to noxious stimulation of the limbs; and (8) spontaneous respirations are not observed when apnea test targets reach pH Conclusions and Relevance This report provides recommendations for the minimum clinical standards for determination of brain death/death by neurologic criteria in adults and children with clear guidance for various clinical circumstances. The recommendations have widespread international society endorsement and can serve to guide professional societies and countries in the revision or development of protocols and procedures for determination of brain death/death by neurologic criteria, leading to greater consistency within and between countries.
295 citations
State University of New York Upstate Medical University1, Heidelberg University2, University of Melbourne3, Capital Medical University4, Harvard University5, Monash University, Clayton campus6, Icahn School of Medicine at Mount Sinai7, Montreal Children's Hospital8, Universidade Federal do Rio Grande do Sul9, Peking University10, University of Southampton11, University of Toronto12, University of Washington13, King Khalid University14, King's College London15, Aga Khan University16, Karolinska Institutet17, Radboud University Nijmegen18, Vrije Universiteit Brussel19, University of Nottingham20, Aarhus University21, University of Cologne22, Trinity College, Dublin23, University of Würzburg24, University of Bergen25, University Medical Center Groningen26, University of Wyoming27, University of California, San Francisco28, University of California, Berkeley29, Nottinghamshire Healthcare NHS Foundation Trust30, Duke University31, University of Amsterdam32, Örebro University33, Chongqing Medical University34, Tel Aviv University35, Washington University in St. Louis36, Federal University of Rio de Janeiro37, University College Cork38, University of British Columbia39, University of Pittsburgh40, Oregon Health & Science University41, University of Montpellier42, University of Ibadan43, University of São Paulo44, Hebrew University of Jerusalem45, University of Sydney46, Jawaharlal Institute of Postgraduate Medical Education and Research47, University of Canterbury48, Autonomous University of Barcelona49, Stellenbosch University50, University of California, Davis51, National Medical College52, Hofstra University53, University of Texas Health Science Center at Houston54, University of Southern Denmark55, University of California, Irvine56, Cardiff University57, Okinawa Institute of Science and Technology58, HU University of Applied Sciences Utrecht59, Katholieke Universiteit Leuven60, University of the Free State61, Johns Hopkins University62, University of Turin63, University of Zurich64
TL;DR: In this article, the authors presented 208 empirically supported statements about ADHD using meta-analysis, which allow for firm statements about the nature, course, outcome causes and treatments for disorders that are useful for reducing misconceptions and stigma.
295 citations
University of Toronto1, Stony Brook University2, University of Alabama at Birmingham3, University of California, San Francisco4, University of Calgary5, Boston Children's Hospital6, University of Catania7, Cleveland Clinic8, Stanford University9, State University of New York System10, University of British Columbia11, University of Ottawa12, University of Helsinki13, Dalhousie University14, Montreal Children's Hospital15, Montreal Neurological Institute and Hospital16
TL;DR: MS in children might be associated with exposure to EBV, suggesting a possible role for EBV in MS pathobiology and children with MS did not differ from controls in seroprevalence of the other childhood viruses studied.
Abstract: Summary Background The full spectrum of clinical manifestations and outcome, and the potential importance of regional or demographic features or viral triggers in paediatric multiple sclerosis (MS), has yet to be fully characterised. Our aim was to determine some of these characteristics in children with MS. Methods 137 children with MS and 96 control participants matched by age and geographical region were recruited in a multinational study. They underwent structured clinical-demographic interviews, review of academic performance, physical examination, disability assessment (MS patients only), and standardised assays for IgG antibodies directed against Epstein-Barr virus, cytomegalovirus, parvovirus B19, varicella zoster virus, and herpes simplex virus. Findings MS was relapsing-remitting at diagnosis in 136 (99%) children. The first MS attack resembled acute disseminated encephalomyelitis (ADEM) in 22 (16%) of the children, most under 10 years old (mean age 7·4 [SD 4·2] years). Children with ADEM-like presentations were significantly younger than were children with polyfocal (11·2 [4·5] years; p Interpretation Paediatric MS is a relapsing-remitting disease, with presenting features that vary by age at onset. MS in children might be associated with exposure to EBV, suggesting a possible role for EBV in MS pathobiology.
294 citations
Authors
Showing all 3844 results
| Name | H-index | Papers | Citations |
|---|---|---|---|
| Paul M. Matthews | 140 | 617 | 88802 |
| Joost J. Oppenheim | 130 | 454 | 59601 |
| Michael Camilleri | 125 | 1084 | 58867 |
| James M. Swanson | 117 | 415 | 47131 |
| Rhian M. Touyz | 114 | 620 | 43738 |
| Ian Roberts | 112 | 714 | 51933 |
| William D. Foulkes | 108 | 682 | 45013 |
| Stephen P. Hinshaw | 106 | 330 | 37336 |
| Michael S. Kramer | 104 | 568 | 43803 |
| Liam Smeeth | 104 | 753 | 53433 |
| Eric Fombonne | 100 | 336 | 44447 |
| Douglas L. Arnold | 100 | 624 | 37040 |
| Erwin W. Gelfand | 99 | 675 | 36059 |
| Frederick Andermann | 90 | 365 | 25638 |
| Robert W. Platt | 88 | 638 | 31918 |